TABLE 1

Key baseline demographics of participants in study

Baseline characteristicTreatmentTotal
myCOPDStandard care
Subjects n293160
COPD severity
 Mild7 (24.1)7 (22.6)14 (23.3)
 Moderate22 (75.9)24# (77.4)#46# (76.7)#
Age years65.9±7.366.4±7.066.1±7.1
Years since COPD diagnosis7.9±6.96.1±5.97.0±6.4
Gender
 Female18 (62.1)11 (35.5)29 (48.3)
 Male11 (37.9)20 (64.5)31 (51.7)
Current smoker7 (24.1)9 (29.0)16 (26.7)
Years of smoking39.0±11.038.6±12.538.8±11.7
≥1 exacerbation (past 3 months)11 (37.9)3 (9.7)14 (25.0)
 Treated with antibiotics10 (34.5)2 (6.5)12 (20.0)
 Treated with steroids8 (27.6)3 (9.7)11 (18.3)
 Requiring emergency department attendance0 (0.0)1 (3.2)1 (1.7)
 Requiring hospitalisation0 (0.0)1 (3.2)1 (1.7)
 Requiring intensive therapy unit admission0 (0.0)0 (0.0)0 (0.0)
 Total duration of stay days0.0±0.00.8±1.50.2±0.8
CAT21.5±8.0)19.8#±5.3#20.6#±6.7#
EQ5D 5L Index Score0.6±0.3)0.7 (0.2)0.6 (0.3)
EQ5D 5L VAS61.9±20.663.3#±19.7#62.6#±20.0#
PAM59.9±15.9)69.0#±13.8)#64.6#±15.4#
PAM level
 16 (20.7)1 (3.2)7 (11.7)
 28 (27.6)2 (6.5)10 (16.7)
 39 (31.0)15# (48.4)#24# (40.0)#
 46 (20.7)13 (41.9)19 (31.7)
SEAMS32.8#±5.7#33.8±4.933.3#±5.3#
Individuals with ≥1 critical error – inhaler technique21 (72.4)18 (58.1)39 (65.0)
Average errors per device1.1±1.31.0±1.11.0±1.2
Daily step count4948.7±1667.69060.1±5135.17591.8±4611.1

Data are presented as n (%) or mean±sd, unless otherwise stated. The denominator for percentages is the number randomised into the study. Three participants with missing data have been included in this table; # denotes variables that were imputed as a result. CAT: COPD assessment test; EQ5D 5L: EuroQol 5 dimensions 5-level questionnaire; VAS: visual analogue scale; PAM: patient activation measurement; SEAMS: self-efficacy for appropriate medication use scale.